Tcbp partners with caredx to support achieve clinical trial using allocell for pharmacokinetic monitoring of allogeneic cell therapy

Edinburgh, scotland , dec. 11, 2024 /prnewswire/ -- tc biopharm (holdings) plc ("tc biopharm" or the "company") (nasdaq: tcbp) a clinical-stage biotechnology company developing platform allogeneic gamma-delta t cell therapies for cancer and other indications, today announced a partnership with caredx, inc. (nasdaq: cdna) the transplant company™ who will perform pharmacokinetic analysis using its allocell™ solution in the achieve clinical trial. the achieve clinical trial is an adaptive, open-label, phase ii study designed to evaluate the efficacy and effectiveness of tcb008, an allogeneic gamma delta t cell therapy for patients with acute myeloid leukemia (aml) or myelodysplastic syndrome (mds).
CDNA Ratings Summary
CDNA Quant Ranking